Latest Ratios: P/E Ratio -27.8x · EV/EBITDA N/A · ROE -27.0%. (2017–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $3.1B | $873M | $1.1B | $492M | $102M | $70M | $387M | — | — | — |
| Enterprise Value | $3.0B | $774M | $935M | $392M | $27M | $-39530000 | $340M | — | — | — |
| P/E Ratio → | -27.83 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 6.28 | 1.90 | 3.42 | 2.00 | — | 0.66 | 4.59 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -27.0% | -27.0% | -32.0% | -84.7% | -250.8% | -25.9% | -33.5% | -1804.8% | — | — |
| ROA | -25.9% | -25.9% | -29.8% | -40.3% | -38.3% | -24.2% | -30.6% | -114.4% | -126.5% | — |
| ROIC | -32.8% | -32.8% | -47.3% | — | — | -110.1% | -23.0% | — | — | — |
| ROCE | -31.1% | -31.1% | -37.6% | -52.3% | -42.8% | -25.8% | -16.4% | -137.9% | -139.8% | -94.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | — | 0.00 | — | 0.00 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | 2.99 |
| Net Debt / Equity | — | -0.21 | -0.40 | -0.41 | — | -1.03 | -0.56 | -0.17 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | -40.77 |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($99M) exceeds total debt ($399000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 28.66 | 28.66 | 19.99 | 10.28 | 8.00 | 19.24 | 14.47 | 7.29 | 4.21 | 12.38 |
| Quick Ratio | 28.66 | 28.66 | 19.99 | 10.28 | 8.00 | 19.24 | 14.47 | 7.29 | 4.21 | 12.38 |
| Cash Ratio | 27.92 | 27.92 | 19.69 | 9.78 | 7.78 | 19.12 | 14.12 | 6.89 | 4.03 | 11.71 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $57M | $47M | $36M | $6M | $8M | $4M | $4M | $4M | $4M |
Clinical trial funding dependency
As reported in financial statements, Enliven Therapeutics trades at a price-to-book ratio of 6.17, a valuation multiple that suggests investors are pricing in the speculative value of its clinical-stage oncology pipeline rather than any near-term earnings, which remain negative at -27.37 on a TTM basis.
The P/B multiple of 6.17 indicates a significant premium over tangible assets, which is typical for biotechnology firms where the primary value resides in intellectual property and clinical trial outcomes. Investors should monitor whether this valuation holds as the company approaches critical data readouts, as the lack of revenue makes traditional P/E metrics largely irrelevant for assessing intrinsic value.
Based on the company's reported figures, the ROIC has remained consistently negative, fluctuating between -5.1% and -12.8% over the last ten quarters, reflecting the inherent difficulty of generating positive returns on invested capital while the firm is entirely focused on high-cost, pre-revenue clinical development.
The persistent negative ROIC is a structural feature of the company's current development stage rather than an indicator of operational failure. This trend suggests that capital is being consumed to build future value, but investors should remain cautious about the long-term compounding potential until the company demonstrates a clear path to commercialization and positive margins.
According to recent SEC filings, the current ratio has shown significant volatility, ranging from 10.28 to 40.32, which indicates that while the company maintains a high level of short-term liquidity, this buffer is being steadily eroded by the ongoing cash requirements of its clinical trial programs.
The high current ratio is primarily a function of the company's cash-heavy balance sheet, which is necessary to fund multi-year R&D cycles. However, the downward trend in total assets suggests that the liquidity position is not self-sustaining, and the company will likely need to access capital markets to maintain its current operational trajectory.
As indicated by the provided financial data, the use of P/E ratios to evaluate Enliven Therapeutics is fundamentally flawed, as the company is pre-revenue and currently generating significant net losses, which renders earnings-based valuation metrics entirely meaningless for assessing the firm's true economic potential.
Investors frequently misapply P/E multiples to clinical-stage biotech firms, which obscures the reality that these companies are essentially R&D engines rather than operating businesses. A more appropriate approach would involve probability-adjusted net present value (rNPV) modeling, which accounts for the likelihood of clinical success and the timing of future commercial cash flows.
Includes 30+ ratios · 9 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ELVN stock.
Enliven Therapeutics, Inc.'s current P/E ratio is -27.8x. This places it at the 50th percentile of its historical range.
Enliven Therapeutics, Inc.'s return on equity (ROE) is -27.0%. The historical average is -75.6%.
Based on historical data, Enliven Therapeutics, Inc. is trading at a P/E of -27.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.